| Dr Long Bao Cao, MD | |
|
1601 Main St Ste 105, Richmond, TX 77469-3230 | |
| (281) 633-4925 | |
| (281) 633-4929 |
| Full Name | Dr Long Bao Cao |
|---|---|
| Gender | Male |
| Speciality | Cardiovascular Disease (cardiology) |
| Experience | 16 Years |
| Location | 1601 Main St Ste 105, Richmond, Texas |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1124281118 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RC0000X | Internal Medicine - Cardiovascular Disease | N8495 (Texas) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Memorial Hermann Memorial City Hospital | Houston, TX | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Memorial Hermann Medical Group | 7012008360 | 590 |
News Archive
Researchers at the University of Eastern Finland and Eberhard Karls Universität Tübingen have discovered a new molecular mechanism that can be used to inhibit the growth of hepatocellular carcinoma, which is the most common liver cancer.
An overabundance of the bacteria Veillonella in the digestive tract may increase pain in patients with sickle cell disease (SCD).
UC Davis investigators have settled a long-standing controversy surrounding the molecular basis of an inherited disorder that historically affected Ashkenazi Jews from Eastern Europe but now also arises in other populations of Semitic descent, particularly families from Saudi Arabia.
ImmunoCellular Therapeutics, a clinical-stage biotechnology company that is developing immune based therapies for the treatment of brain and other cancers, announced today that the Company and Torrey Pines Institute for Molecular Studies in San Diego, CA have identified several peptides which can generate CD-133 specific T-cells. CD-133 is found in high abundance on cancer stem cells ("CSCs") which makes it promising for immunological targeting.
› Verified 2 days ago
| Entity Name | Oakbend Medical Group |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1366480725 PECOS PAC ID: 7517917867 Enrollment ID: O20050125000741 |
News Archive
Researchers at the University of Eastern Finland and Eberhard Karls Universität Tübingen have discovered a new molecular mechanism that can be used to inhibit the growth of hepatocellular carcinoma, which is the most common liver cancer.
An overabundance of the bacteria Veillonella in the digestive tract may increase pain in patients with sickle cell disease (SCD).
UC Davis investigators have settled a long-standing controversy surrounding the molecular basis of an inherited disorder that historically affected Ashkenazi Jews from Eastern Europe but now also arises in other populations of Semitic descent, particularly families from Saudi Arabia.
ImmunoCellular Therapeutics, a clinical-stage biotechnology company that is developing immune based therapies for the treatment of brain and other cancers, announced today that the Company and Torrey Pines Institute for Molecular Studies in San Diego, CA have identified several peptides which can generate CD-133 specific T-cells. CD-133 is found in high abundance on cancer stem cells ("CSCs") which makes it promising for immunological targeting.
› Verified 2 days ago
| Entity Name | Memorial Hermann Medical Group |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1003985102 PECOS PAC ID: 7012008360 Enrollment ID: O20070801000368 |
News Archive
Researchers at the University of Eastern Finland and Eberhard Karls Universität Tübingen have discovered a new molecular mechanism that can be used to inhibit the growth of hepatocellular carcinoma, which is the most common liver cancer.
An overabundance of the bacteria Veillonella in the digestive tract may increase pain in patients with sickle cell disease (SCD).
UC Davis investigators have settled a long-standing controversy surrounding the molecular basis of an inherited disorder that historically affected Ashkenazi Jews from Eastern Europe but now also arises in other populations of Semitic descent, particularly families from Saudi Arabia.
ImmunoCellular Therapeutics, a clinical-stage biotechnology company that is developing immune based therapies for the treatment of brain and other cancers, announced today that the Company and Torrey Pines Institute for Molecular Studies in San Diego, CA have identified several peptides which can generate CD-133 specific T-cells. CD-133 is found in high abundance on cancer stem cells ("CSCs") which makes it promising for immunological targeting.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Long Bao Cao, MD 4911 Sandhill Dr, Sugar Land, TX 77479-5320 Ph: (281) 238-7870 | Dr Long Bao Cao, MD 1601 Main St Ste 105, Richmond, TX 77469-3230 Ph: (281) 633-4925 |
News Archive
Researchers at the University of Eastern Finland and Eberhard Karls Universität Tübingen have discovered a new molecular mechanism that can be used to inhibit the growth of hepatocellular carcinoma, which is the most common liver cancer.
An overabundance of the bacteria Veillonella in the digestive tract may increase pain in patients with sickle cell disease (SCD).
UC Davis investigators have settled a long-standing controversy surrounding the molecular basis of an inherited disorder that historically affected Ashkenazi Jews from Eastern Europe but now also arises in other populations of Semitic descent, particularly families from Saudi Arabia.
ImmunoCellular Therapeutics, a clinical-stage biotechnology company that is developing immune based therapies for the treatment of brain and other cancers, announced today that the Company and Torrey Pines Institute for Molecular Studies in San Diego, CA have identified several peptides which can generate CD-133 specific T-cells. CD-133 is found in high abundance on cancer stem cells ("CSCs") which makes it promising for immunological targeting.
› Verified 2 days ago
Dr. Rajat S. Bhatt, MD Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 7103 S Peek Rd Unit B-1, Richmond, TX 77407 Phone: 281-884-9705 Fax: 888-844-2976 | |
Dr. Hoang M Phan, M.D. Cardiovascular Disease Medicare: May Accept Medicare Assignments Practice Location: 20110 Stoneview Dr, Richmond, TX 77407 Phone: 832-798-7326 | |
Maya Susan Varkey, NP Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 8119 Cheyenne Hills Trl, Richmond, TX 77406 Phone: 773-430-5838 | |
Nitesh Vachhani, MD Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 1601 Main St Ste 401, Richmond, TX 77469 Phone: 281-342-9530 Fax: 281-342-9564 | |
Dr. Aisha B Khattak, M.D. Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 8002 Fm 1464 Rd Ste 300, Richmond, TX 77407 Phone: 832-400-2733 Fax: 832-400-2734 | |
Dr. James R. Mcclamroch, M.D. Cardiovascular Disease Medicare: Medicare Enrolled Practice Location: 22001 Southwest Fwy, Suite 210, Richmond, TX 77469 Phone: 281-238-7825 |